57 /100
HIGH RISK
Score updated Jul 14, 2026

SCNI — Scinai Immunotherapeutics Ltd. Dilution Risk Tracker

Track SCNI dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track SCNI — Get alerts when the score changes →

As of July 14, 2026, Scinai Immunotherapeutics Ltd. (SCNI) has a DilutionWatch DilutionScore of 57/100, rated HIGH dilution risk. Scinai Immunotherapeutics Ltd. has a market capitalization of $1.78M, 13.87B shares outstanding, 7 institutional holders tracked. Key dilution vectors include 1.64M outstanding warrants, approximately 3 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
85
📊 Float Risk
0
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
45%
🔄 Reverse Split 70%
• 50-day avg $0.58 below $1 exchange minimum
• Only 3 months cash — financial pressure
💰 Capital Raise 35%
• Low cash runway: 3 months remaining
🔔 Track SCNI — Get forecast alerts →

💹 Market Data

Market Cap$1.78M
Shares Outstanding13.87B
FloatN/A
Cash$1.66M
Debt$382.0K
Short InterestN/A

🏛 Institutional Holdings

7 institutional holders · 81.9K shares
#1 Citadel Advisors Llc 34.6K shares
#2 Xtx Topco Ltd 27.3K shares
#3 Virtu Financial LLC 15.4K shares
+ 4 more holders Sign up free to view →

📉 Short Interest

Short Interest26.9K
Days to Cover1.0
% of FloatN/A
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Jul 31, 2025
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for SCNI Shareholders

Scinai Immunotherapeutics Ltd. (SCNI) has a DilutionScore of 57/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch tracks 1.6M outstanding warrants for SCNI. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: SCNI has approximately 3 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for SCNI in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for SCNI alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →
Track SCNI Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking SCNI — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for SCNI
📊 SCNI FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 SCNI Signal Convergence & Dark Pool Activity — StonkWhisper 📄 SCNI Dilution Risk Analysis — Full In-Depth Report

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.